Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 97 publications.

Bello N, Meyers KJ, Workman J, Marcano Belisario J, Cervera R. Systematic literature review and meta-analysis of venous thromboembolism events in systemic lupus erythematosus. Rheum Ther. 2022 Dec 6. doi: 10.1007/s40744-022-00513-1

Joly F, DasMahapatra P, Su J, DiBenedetti D, Kosa K, Hill QA. Creation of a cold agglutinin disease (CAD) specific patient-reported outcome (PRO) symptom measure. Poster presented at the 84th Annual Meeting of the Japanese Society of Hematology; October 14, 2022. Fukuoka, Japan.

Xu X, Datto C, Kwiatek J, Meyers J, Candrilli S, Mines D, Stirnadel-Farrant H. Comparison of healthcare resource utilization and costs in patients with and without Bullous Pemphigoid: a retrospective analysis of US health insurance claims data. Poster presented at the ISPOR 2022 Conference; May 18, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

Kamudoni P, Amtmann D, Johns J, Cook KF, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Barrett A, Olayinka-Amao B, Henke C. The validity, responsiveness, and score interpretation of the PROMISnq Physical Function - Multiple Sclerosis 15a short form in multiple sclerosis. Mult Scler Relat Disord. 2022 Jun;62:103753. doi: 10.1016/j.msard.2022.103753

Anderson-Smits C, Mitchell S, Hawe E, Hartley L. Use of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy: a systematic literature review. Poster presented at the 2022 Peripheral Nerve Society (PNS) Annual Meeting; May 14, 2022. Miami, FL.

Ogdie A, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh J. Experiences and treatment preferences in patients with psoriatic arthritis: a cross-sectional study in the ArthritisPower registry. Rheum Ther. 2022 Apr;9(2):735-51. doi: 10.1007/s40744-022-00436-x

Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Subcutaneous immunoglobulin use in immunoglobulin-naïve patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022 Apr;14(5):373-87. doi: 10.2217/imt-2021-0265

Anderson-Smits C, Orange J, Park M, Huang Z, Layton JB, Ritchey ME. Immunoglobulin initiation among patients with primary immunodeficiency diseases: a retrospective claims-based United States cohort study. Presented at the AMCP 2022 Meeting; March 29, 2022. Chicago, IL.

Strand V, Kaeley GS, Bergman MJ, Gladman DD, Coates LC, Sherif B, Hur P, Parikh B, Gilloteau I, Mease PJ. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomized phase 3 trial. Lancet Rheumatol. 2022 Mar 1;4(3):e208-19.

Wyrwich KW, Winnette R, Bender R, Gandhi K, Williams N, Harris N, Nelson L. Validation of the alopecia areata patient priority outcomes (AAPPO) questionnaire in adults and adolescents with alopecia areata. Dermatol Ther. 2022 Jan;12(1):149-66. doi: 10.1007/s13555-021-00648-z

Joly F, DasMahapatra P, Su J, DiBenedetti D, Kosa K, Hill Q. Development of a cold Agglutinin disease-specific patient-reported outcome symptom measure. Poster presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 13, 2021. [abstract] Blood. 2021 Nov 23; 138(supplement 1):4057. doi: 10.1182/blood-2021-147199

Walsh J, Myers K, Mansfield C, Tillett W, Nash P, Leach C, Nowell W, Gavigan K, Zueger P, McDearmon-Blondell E, Ogdie-Beatty A. Impact of treatment experience on patient preferences and disease burden in psoriatic arthritis: results from a rheumatology patient research registry. Poster presented at the 2021 Virtual ACR Convergence; November 8, 2021.

Inui K, Sato M, Esterberg E, Parikh RC, Kimura S, Torisu-Itakura H. Treatment practices and costs among patients with psoriatic arthritis: a Japanese hospital claims database analysis. Mod Rheumatol. 2021 Nov;31(6):1179-91. doi: 10.1080/14397595.2021.1886629

Gold BD, Goodwin B, Davis K, Sweeney C, Ziemiecki R, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Patient satisfaction and adherence to corticosteroids in adolescents and adults with eosinophilic esophagitis in a real-world setting in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S177.

Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Intravenous immunoglobulin initiation in chronic inflammatory demyelinating polyradiculoneuropathy: a retrospective claims-based cohort study. Poster presented at the 2021 American Association of Neuromuscular & Electrodiagnostic Medicine Conference; October 2021. Aurora, CO. Previously presented at the 2021 Peripheral Nerve Society Virtual Meeting.

Houghton K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of Secukinumab. Dermatol Ther. 2021 Aug;11(4):1373-84. doi: 10.1007/s13555-021-00564-2

Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Intravenous immunoglobulin initiation in chronic inflammatory demyelinating polyradiculoneuropathy: a retrospective claims-based cohort study. Poster presented at the 2021 Peripheral Nerve Society Virtual Meeting; June 12, 2021.

Anderson-Smits C, Layton JB, Ritchey ME, Chavan S, Souayah N. Intravenous immunoglobulin treatment patterns in chronic inflammatory demyelinating polyradiculoneuropathy patients: a US claims database analysis. Poster presented at the 2021 Peripheral Nerve Society Virtual Meeting; June 12, 2021.

Ogdie A, Mansfield C, Myers K, Tillett W, Nash P, Leach C, Nowell WB, Gavigan K, Zueger P, McDearmon-Blondell E, Walsh JA. Real-world patient experience and treatment preferences in patients with psoriatic arthritis. Poster presented at the Virtual EULAR 2021 Congress; June 2, 2021. [abstract] Ann Rheum Dis. 2021 Jun; 80(Suppl 1):237. doi: 10.1136/annrheumdis-2021-eular.852

Winnette R, Wyrwich K, Bender R, Gandhi K, Williams N, Harris N, Nelson L. Validation of AAPPO Questionnaire in adults and adolescents with alopecia areata. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.

Anderson-Smits C, Huang Z, Ritchey MB, Layton JB. Procedure coding versus pharmacy-dispensing claims for assessing steroid use in patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Primary Immunodeficiency Diseases (PIDD). Poster presented at the Virtual ISPOR 2021 Conference; May 2021.

Layton JB, Ritchey MB, Huang Z, Anderson-Smits C. Replicating clinical trial exclusion criteria in a claims-based cohort of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) treatment. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.

Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting; April 17, 2021. Previously presented at the 2020 Muscle Study Group (MSG) Annual Virtual Meeting.

Anderson-Smits C, Orange J, Park M, Huang Z, Layton JB, Ritchey ME. Immunoglobulin initiation among patients with Primary Immunodeficiency Diseases (PIDD): a retrospective claims-based US cohort study. Poster presented at the 2021 Clinical Immunology Society (CIS) Virtual Meeting; April 14, 2021.

Winnette R, Martin S, Harris N, Deal LS. Development of the alopecia areata patient priority outcomes instrument: a qualitative study. Dermatol Ther. 2021 Apr;11(2):599-613. doi: 10.1007/s13555-021-00508-w

Baraliakos X, Van den Bosch F, Machado PM, Gensler LS, Marzo-Ortega H, Sherif B, Quebe-Fehling E, Porter B, Gaillez C, Deodhar A. Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies. Rheum Ther. 2021 Mar;8(1):273-88. doi: 10.1007/s40744-020-00269-6

Bell CF, Lau M, Lee M, Poulos C. Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE. Clin Rheumatol. 2021 Feb;40(2):581-90. doi: 10.1007/s10067-020-05226-w

Su J, Kosa K, DiBenedetti D. Patient-reported disease burden: in-depth interviews of patients with CAD. Poster presented at the 2020 Virtual 62nd ASH Annual Meeting and Exposition; December 6, 2020. [abstract] Blood. 2020 Nov 5; 136(Suppl 1):29-30.

Fernandez M, Mordin M, Neighbors M, Tzivelekis S. A targeted literature review on the burden of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Poster presented at the 2020 Virtual German Neurological Society (DGN) Congress; November 4, 2020. Previously presented at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Conference..

Stull K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase III clinical trials. Poster presented at the 2020 Virtual 29th European Academy of Dermatology and Venerology Congress; October 28, 2020.

Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the IgNS Virtual 2020 9th National Conference; October 22, 2020.

Layton JB, Anderson-Smits C, Ritchey ME, Chavan S, Souayah N. Treatment patterns of US patients with chronic inflammatory demyelinating polyradiculoneuropathy. Poster presented at the 2020 Virtual American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting; October 2020. [abstract] Muscle Nerve. 2020 Oct; p.126.

Layton JB, Ritchey ME, Huang Z, Anderson-Smits C, Hill G. Identifying immunoglobulin use in claims data with procedure coding and pharmacy dispensing data. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Layton JB, Ritchey ME, Huang Z, Anderson-Smits C. Comparability of patients with CIDP using intravenous immunoglobulin in Medicaid vs commercial or Medicare claims data. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.

Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the 2020 Muscle Study Group (MSG) Annual Virtual Meeting; September 25, 2020. [abstract] RRNMF Neu J. 2020 Sep; 1(4):61.

Tomita T, Sato M, Esterberg E, Parikh RC, Hagimori K, Nakajo K. Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: a hospital claims database analysis. Mod Rheumatol. 2020 Jun 19;1-11. doi: 10.1080/14397595.2020.1775927

Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, Young P, Cappelleri JC, Brown TM, Ervin C, Hsu M-A, Fallon L. Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study. Patient Prefer Adherence. 2020 Jun 8;2020(14):949-61. doi: 10.2147/PPA.S242336

Layton JB, Anderson-Smits C, Ritchey ME, Chavan S, Souayah N. Treatment patterns of a large US sample of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) patients. Poster presented at the 2020 6th EAN Congress Virtual Congress; May 23, 2020.

Anderson-Smits C, Layton JB, Ritchey ME, Hayden V, Sehinovych I, Chavan S, Souayah N. Patient and treatment characteristics of a large US sample of patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) initiating Intravenous Immunoglobulin (IVIG) therapy. Poster presented at the 2020 Virtual American Academy of Neurology Annual Meeting (Conference cancelled); April 25, 2020. Toronto, Canada. [abstract] Neurology. 2020 Apr 14; 94(15 Supplement):4442.

Fernandez M, Mordin M, Neighbors M, Tzivelekis S. A targeted literature review on the burden of chronic inflammatory demyelinating polyneuropathy. Poster presented at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Conference; October 16, 2019. Austin, TX. [abstract] Muscle Nerve. 2019 Sep; p.112.

Himmler S, Mueller M, Sherif B, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev Pharmacoecon Outcomes Res. 2019 Jul 29. doi: 10.1080/14737167.2019.1644169

DiBenedetti D, McLeod L, Williams N, Coles T, Tzivelekis S, Meckley LM. Development and validation of the IG Patient Experience with Treatment (IGPET), a novel patient-reported measure for individuals with primary immunodeficiency diseases. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

Ajmera M, Parikh R, Meyers J. Autoimmune disorders among adults with asthma: an economic outlook. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.

DiBenedetti D, Tzivelekis S, Meckley L. Humanistic cost impacts associated with immunoglobulin replacement therapy among patients with primary immunodeficiency disease in the United States. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. San Diego, CA. [abstract] J Manag Care Pharm. 2019 Mar; 25(3-a Suppl):S37.

Meckley L, Coles T, Williams N, DiBenedetti D, McLeod L. Experience with immunoglobulin treatment among patients with PIDD in the US. Poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting; February 22, 2019. San Francisco, CA. [abstract] J Allergy Clin Immunol. 2019 Feb; 143(2 Supplement):AB112. doi: 10.1016/j.jaci.2018.12.341

Coles T, Meckley LM, McLeod L, Williams N, DiBenedetti D, Devercelli G. Psychometric evaluation of the immunoglobulin patient experience with treatment (IgPET) in primary immunodeficiency diseases. Poster presented at the 25th Annual International Society for Quality of Life Research Conference (ISOQOL); October 26, 2018. Dublin, Ireland.

Coates L, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK. Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-35. doi: 10.1002/acr.23537

Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.

Mease PJ, Gladman DD, Davenport EK, Zhou X, Guerette B, Teng L, Kaura S, Nash P. Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomized, controlled study in biologic-naive subjects with active psoriatic arthritis. Poster presented at the 5th World Psoriasis & Psoriatic Arthritis Conference 2018; June 27, 2018. Stockholm, Sweden. [abstract] Acta Derm Venereol. 2018 Jun; 98(Suppl 219):14. Previously presented at the 2017 ACR/ARHP Annual Meeting. doi: 10.2340/00015555-2978

Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018 Feb;21(2):163-73. doi: 10.1080/13696998